We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




GlaxoSmithKline Boosts Global Cancer Testing With GE Healthcare Deal

By LabMedica International staff writers
Posted on 19 Oct 2014
Print article
The new agreement between GE Healthcare-subsidiary Clarient (Aliso Viejo, CA, USA) and GlaxoSmithKline (GSK; Brentford, UK) will create a force in cancer testing, according to Kalorama Information (New York City, NY, USA).

The two entities will form a multipurpose, data analytics- and companion diagnostics (CDx)-driven network of laboratories. Kalorama recently released its report "Companion Diagnostics Market" on drug-test combinations such as those envisioned in this deal. “The trend in cancer testing is that companies, even large entities, can’t do it alone,” said Bruce Carlson, publisher of Kalorama Information, “This is one example of a partnership between a test manufacturer and a maker of biopharmaceuticals.”

While operational details of the agreement have yet to be provided, certain parameters already announcement highlight unique benefits of CDx partnerships. GE Healthcare, Clarient, and GSK will certify laboratories around the world to perform cancer diagnostic tests, with initial network labs expected in 2015. Clarient’s laboratory expertise includes immunohistochemistry (IHC), flow cytometery, qPCR, [fluorescent] in-situ hybridization ([F]ISH), cytogenetic karyotyping, microarrays, and next-generation sequencing (NGS). Testing will focus initially on 70 melanoma-specific mutations, including the CDx-targeted BRAF V600E and V600K genes.

Testing performed at networked labs will feed an associated data analytics service to be made available by GE Healthcare as a subscription. GSK will presumably be provided the same service to aid its biopharmaceutical development. The lab and data analytics service will be available to clients including pharmaceutical market participants, payers, and other healthcare organizations. Patient testing data can be used dynamically to improve patient care and personalized treatments, perform geospatial analysis, epidemiological analysis, and to recruit patients to oncology-related clinical trials.

Kalorama said that in this move GSK is competing with pharmaceutical-diagnostics leader Roche, which has already released a Zelboraf (vemurafenib) treatment pairing with BRAF V600 mutation, and has released Phase III trial data on adding cobimetinib, also for BRAF V600 mutation-positive melanoma patients. GSK has successfully developed products through IVD partnerships before: GSK and bioMérieux developed the THxID BRAF CDx qPCR test kit (FDA approved, May 2013) to identify melanoma patients with the BRAF V600E or V600K gene mutation and thus candidates for treatment with Tafinlar and Mekinist.

Kalorama’s report contains information on CDx drug-test combinations including market size and forecasts, key players and important trends.

Related Links:

Kalorama Information
Companion Diagnostics Market report
Clarient


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.